Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Source: View publication →
In patients with heart failure and a mildly reduced or preserved ejection fraction, the nonsteroidal mineralocorticoid receptor antagonist finerenone significantly reduced the composite rate of total worsening heart failure events and cardiovascular death.
Key Findings
Study Design
Study Limitations
Clinical Significance
FINEARTS-HF definitively establishes a robust role for mineralocorticoid receptor antagonism in patients with mildly reduced or preserved ejection fraction (HFmrEF and HFpEF). It solidifies finerenone as a key pillar of guideline-directed medical therapy for this population alongside SGLT2 inhibitors, resolving a major area of clinical uncertainty left in the wake of previous ambiguous trials.
Historical Context
For decades, steroidal mineralocorticoid receptor antagonists (MRAs) like spironolactone and eplerenone have been foundational, mortality-reducing therapies for heart failure with reduced ejection fraction (HFrEF) following landmark trials like RALES and EMPHASIS-HF. However, their role in patients with an ejection fraction of 40% or higher remained highly controversial due to the TOPCAT trial (2014), which failed to meet its primary endpoint globally. Retrospective analyses of TOPCAT suggested efficacy in the Americas cohort that was masked by severe non-adherence in the Russia and Georgia cohorts. FINEARTS-HF finally provides the much-awaited, prospective evidence that MRA therapy is safe and effective across the higher ejection fraction spectrum.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of finerenone differ from traditional steroidal MRAs like spironolactone, and why might this nonsteroidal structure be advantageous in treating heart failure patients with preserved ejection fraction?
Key Response
Finerenone is a nonsteroidal, highly selective mineralocorticoid receptor antagonist. It binds to the receptor differently than spironolactone, recruiting distinct co-factors and having a shorter half-life with less tissue accumulation. This translates clinically to a lower risk of hyperkalemia and fewer anti-androgenic side effects (like gynecomastia), while maintaining potent anti-fibrotic and anti-inflammatory effects in the heart and kidneys.
When initiating a patient with HFpEF on finerenone based on the FINEARTS-HF trial, what specific laboratory parameters must be monitored, and how does the management of hyperkalemia differ in the context of MRAs compared to other GDMT?
Key Response
Finerenone requires careful monitoring of serum potassium and renal function (eGFR). Although it causes less hyperkalemia than steroidal MRAs, the risk remains a primary clinical concern. Residents must check potassium 1 and 4 weeks after initiation or dose changes. If mild hyperkalemia occurs, modern management emphasizes using potassium binders (like patiromer or SZC) to allow continuation of life-saving GDMT rather than abruptly discontinuing the MRA.
The FINEARTS-HF trial demonstrated a reduction in total worsening heart failure events. How does the mechanistic benefit of finerenone complement that of SGLT2 inhibitors in HFpEF, and what does the data suggest about their concurrent use?
Key Response
Fellows must integrate evidence across trials. While SGLT2 inhibitors (DELIVER, EMPEROR-Preserved) address metabolic, hemodynamic, and diuretic pathways, finerenone primarily targets maladaptive fibrosis and inflammation. Concurrent use is synergistic; importantly, the mild diuretic and uricosuric effects of SGLT2 inhibitors are known to mitigate the hyperkalemia risk associated with MRAs, allowing better tolerability and optimization of quadruple therapy even in HFmrEF/HFpEF phenotypes.
Given the historical controversy and mixed results of steroidal MRAs (like spironolactone in the TOPCAT trial) in the HFpEF population, how do the results of FINEARTS-HF definitively reframe our understanding of mineralocorticoid receptor antagonism in this phenotype?
Key Response
TOPCAT failed to meet its primary endpoint overall, largely due to regional disparities (the Americas showed benefit, while Russia/Georgia did not, with questionable medication adherence). FINEARTS-HF provides definitive, global RCT evidence that MR antagonism is indeed a valid, efficacious target in HFpEF/HFmrEF. Attendings can use this to confidently teach that the MRA pathway is critical across the entire LVEF spectrum, shifting practice away from the therapeutic nihilism that previously surrounded HFpEF.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
FINEARTS-HF evaluated 'total worsening heart failure events' using a recurrent-events statistical analysis rather than a traditional time-to-first-event Cox proportional hazards model. What are the statistical advantages of this approach, and how must researchers account for informative censoring?
Key Response
Recurrent events analysis (like the Lin-Wei-Ying-Wei model) increases statistical power and better reflects the true cumulative burden of heart failure, where patients often suffer multiple hospitalizations. However, a major methodological challenge is informative censoring, where a terminal event (cardiovascular death) stops the recurrent event process. Researchers must utilize joint frailty models to simultaneously evaluate recurrent events and death to ensure unbiased treatment effect estimates.
As SGLT2 inhibitors became standard of care for HFpEF during the enrollment period of FINEARTS-HF, what specific subgroup analyses and methodological safeguards would you demand as an editor to ensure the observed benefit of finerenone is not subject to time-varying confounding?
Key Response
A tough reviewer would flag the rapidly evolving background standard of care. It is crucial to verify that the randomization remained balanced over time as baseline SGLT2 inhibitor use increased. The editor would demand robust subgroup analyses stratified by baseline SGLT2i use to prove that finerenone provides independent, additive efficacy on top of modern contemporary therapy, ensuring the trial's internal validity and contemporary relevance.
Current AHA/ACC/HFSA guidelines give MRAs a Class 2b recommendation in HFpEF based largely on TOPCAT. With the positive results of FINEARTS-HF, should finerenone receive a Class 1 or 2a recommendation, and should guidelines designate this as a class effect for all MRAs or exclusively for finerenone?
Key Response
Guidelines currently position SGLT2 inhibitors as the only strongly recommended therapy (Class 2a/1) for HFpEF. FINEARTS-HF provides robust, Level A evidence that supports elevating finerenone. The committee must debate whether to upgrade MRAs as a general class (extrapolating TOPCAT's Americas data with FINEARTS-HF) or specifically grant a strong recommendation only to finerenone due to its distinct nonsteroidal profile and definitive trial success.
Clinical Landscape
Noteworthy Related Trials
TOPCAT Trial
Tested
Spironolactone 15-45 mg daily
Population
Patients with symptomatic heart failure and LVEF >=45%
Comparator
Placebo
Endpoint
Composite of cardiovascular death, aborted cardiac arrest, or hospitalization for heart failure
EMPEROR-Preserved Trial
Tested
Empagliflozin 10 mg daily
Population
Patients with heart failure and LVEF >40%
Comparator
Placebo
Endpoint
Composite of cardiovascular death or hospitalization for heart failure
DELIVER Trial
Tested
Dapagliflozin 10 mg daily
Population
Patients with heart failure and mildly reduced or preserved LVEF (>40%)
Comparator
Placebo
Endpoint
Composite of worsening heart failure or cardiovascular death
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis